Golden Helix Inc., a leading bioinformatics solutions provider, has now announced the integration of MedGenome’s OncoMD into their VarSeq software. The integration will provide VarSeq users with the option to access over 2 million annotated cancer variants.
OncoMD is a comprehensive knowledge base of cancer-specific genetic alterations captured from peer-reviewed scientific publications by a team of biomedical curators. After filtering variants of interest using VarSeq, customers can quickly prioritize actionable variants using OncoMD and make clinical decisions based on sensitivity of variants to approved drugs and enrollment to open clinical trials.
Read the article at Pharmabiz